BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Boa ...

BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4. To access a live webcast of the presentation, please visit the Investors section o ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Amanda Morgan - Chief Commercial Officer Conference Call Participants Anthony Petrone - Mizuho Group Roanna Ruiz - Leerink Partners Richard Newitter - Truist Securities Matt Taylor - Jefferies Tara Bancroft - TD Cowen Larry Solow - CJS Securities Yuan Zhi - B. Ri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) (Registrant's telephone number, ...

Exhibit 99.1 Second Quarter 2024 • Completed three strategic transactions to expand innovative pipeline • The Company maintains full year 2024 revenue guidance and updates fully diluted earnings per share guidance driven by strategic transactions "We delivered another strong quarter as we continued to maximize the value of our commercial portfolio," said Brian Markison, Chief Executive Officer of Lantheus. "With the strength of our balance sheet and radiopharmaceutical expertise, we also announced three str ...

Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of interquarter investment in business development and R&D. The Company maintains full year 2024 revenue guidance and updates fully diluted earnings per share gui ...

Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus.com Melissa Downs Senior Director, External Communications 646-975-2533 media@lantheus.com BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second quarter of 2024. To access the conference call or webcast, pa ...

To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has ...

About Lantheus Melissa Downs Senior Director, External Communications 646-975-2533 media@lantheus.com Through this acquisition, Lantheus now has the worldwide exclusive rights to ß amyloid PET (positron emission tomography) imaging agent, NAV-4694, also known as F18-flutafuranol. NAV-4694 is currently in Phase 3 development and is also being used in academic and industry investigational therapeutic trials. The acquisition of this asset broadens Lantheus' Alzheimer's diagnostic portfolio and complements Lant ...

BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services' (CMS') Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to support ...